Skip to main content
Apeloa Pharmaceutical Co.,Ltd. logo

Apeloa Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 000739 ISIN · CNE000000Q45 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,841 across all filing types
Latest filing 2025-05-15 Notice of Dividend Amou…
Country CN China
Listing Shenzhen Stock Exchange 000739

About Apeloa Pharmaceutical Co.,Ltd.

https://www.apeloa.com

Apeloa Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and distribution of active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. The company operates three core business pillars: API production, Contract Development and Manufacturing Organization (CDMO) services, and finished drug products. Its therapeutic focus includes cardiovascular, anti-infective, anti-viral, and oncology treatments. Apeloa utilizes an integrated supply chain to deliver chemical and biological solutions to a global client base. The organization maintains compliance with international quality standards, including certifications from the FDA, EMA, and PMDA. Its CDMO services encompass the full product lifecycle, from process chemistry and analytical development to large-scale commercial manufacturing, supported by specialized technology platforms such as continuous flow chemistry and enzymatic synthesis.

Recent filings

Filing Released Lang Actions
2024年度分红派息实施公告
Notice of Dividend Amount Classification · 95% confidence The document is a detailed announcement regarding the implementation of the 2024 annual dividend distribution by 普洛药业股份有限公司. It includes specifics about the dividend amount, the shareholder meeting approval, the record date, ex-dividend date, and the method of dividend payment. It also discusses adjustments related to share repurchases and tax details. The document is not a full annual report or financial statement but an official announcement of dividend payment details following shareholder approval. It fits the definition of a Notice of Dividend Amount (DIV) rather than an Annual Report or Earnings Release. The document length is about 3,022 characters, which is consistent with an announcement rather than a full report. Therefore, the correct classification is DIV with high confidence.
2025-05-15 Chinese
关于首次回购公司股份暨回购股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the company's first share repurchase and progress of the share buyback plan. It details the board resolutions approving the buyback, the number of shares repurchased, prices, and compliance with regulatory rules. It does not contain financial statements or detailed financial analysis but is a regulatory disclosure about share repurchase activity. This fits the definition of a Transaction in Own Shares (POS) filing, which reports on the company buying back its own shares.
2025-05-05 Chinese
关于对下属公司担保的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from 普洛药业股份有限公司 regarding the progress of guarantees provided to its subsidiaries. It details specific guarantee contracts signed with various banks, the amounts, terms, and the financial status of the guaranteed subsidiaries. It also includes the board's opinion on the guarantees and cumulative guarantee amounts. The document is a formal disclosure about financing guarantees, not a full financial report, earnings release, or management discussion. It is not a report publication announcement since it contains substantive details about the guarantees and related financial data. The content fits best under Capital/Financing Update (CAP) as it relates to financing activities and guarantees provided by the company to its subsidiaries.
2025-05-05 Chinese
第九届董事会第十三次会议决议公告
Transaction in Own Shares Classification · 95% confidence The document is a board meeting resolution announcement from 普洛药业股份有限公司, detailing the approval of a proposal related to increasing funds for share repurchase. It includes voting results and meeting details but does not contain financial statements or detailed financial data. The content focuses on a board decision regarding share repurchase funding, which aligns with announcements about share repurchase or issuance activities. Given the nature of the content and the specific mention of share repurchase funding, the document fits best under the category of Transaction in Own Shares (POS). The document length is short and it is not a report or a regulatory filing but a specific announcement of a board resolution related to share repurchase.
2025-04-25 Chinese
关于增加回购股份资金来源的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the adjustment of the funding source for a share repurchase program by the company 普洛药业股份有限公司. It details the change from using solely 'own funds' to 'own funds and bank loans' for the stock buyback. The document includes specifics about the board meeting approval, loan commitment from a bank, and compliance with regulatory requirements. It does not contain financial statements or detailed financial results but is focused on the update about the share repurchase funding source. This fits the category of a Transaction in Own Shares (POS) filing, which covers announcements related to share buybacks or repurchases.
2025-04-25 Chinese
关于注销回购股份减少注册资本暨通知债权人的公告
Share Issue/Capital Change Classification · 95% confidence The document is an official announcement from 普洛药业股份有限公司 regarding the cancellation of repurchased shares and the consequent reduction of registered capital. It details the board and shareholder meeting approvals, the number of shares to be cancelled, the impact on registered capital, and a notification to creditors about their rights to claim debts within a specified period. The document is a formal public notice about a corporate action affecting capital structure and creditor rights, not a financial report or detailed analysis. It does not contain financial statements or management discussion but serves as a regulatory announcement to inform stakeholders of the capital change and related procedures. Therefore, it fits the category of Share Issue/Capital Change (SHA). The document length is short (1394 characters), and it is not merely announcing the publication of a report but is itself the announcement of a capital change event.
2025-04-18 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.